Sign Out
Special instructions for use, handling and disposal: Bevacizumab infusions should not be administered or mixed with Dextrose or Glucose solutions.
Do not administer as an intravenous push or bolus.
Bevacizumab should be prepared by a healthcare professional using aseptic technique. Use sterile needle and syringe to prepare Bevacizumab. Withdraw the necessary amount of Bevacizumab and dilute to the required administration volume with 0.9% Sodium chloride solution. The concentration of the final Bevacizumab solution should be kept within the range of 1.4 mg/mL - 16.5 mg/mL.
Discard any unused portion left in a vial, as the product contains no preservatives. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.
Bevacizumab is not formulated for intravitreal use.
Chemical and physical infusion stability has been demonstrated for 48 hours at 2°C - 8°C and at room temperature in 0.9% sodium chloride solution. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally not be longer than 24 hours at 2°C - 8°C, unless dilution has taken place in controlled and validated aseptic conditions.
Incompatibilities: No incompatibilities between Bevacizumab and polyvinyl chloride or polyolefine bags have been observed. A concentration-dependent degradation profile of Bevacizumab was observed when diluted with Dextrose solutions (5%).
Disposal of unused/expired medicines: The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed via wastewater and disposal through household waste should be avoided. Use established "collection systems", if available in the location.
